When short-course ATRi is integrated with RT, treatment elicits preferential expansion of tumor antigen–specific CD8+ T cells in the DLN, the lymphoid site in tumor-bearing mice that is crucial for the efficacy of PD-1/PD-L1 checkpoint blockade (32). This evidence concerns the gene CD8A and neoplasm.